Study Name:
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults with Eosinophilic Asthma
Targeted Disease(s):
Asthma
Purpose of Study:
The purpose of this study, EXHALE-4, is to assess the efficacy and safety of Dexpramipexole, an oral eosinophil maturation inhibitor, in patients ≥12 years of age with inadequately controlled moderate-severe eosinophilic asthma (GINA Step 3, 4, or 5). The primary endpoint of this study is change in lung function (FEV1) from baseline.
Study Dates:
January 30, 2023 - December 30, 2024
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Areteia Therapeutics
Contact:
EXHALE Recruiting: 888-584-9281
[email protected]
ClinicalTrails.gov Identifier:
NCT05748600
